Which companies overlap with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's portfolio?

Top competitors by shared drug class: AstraZeneca, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Immatics Biotechnologies GmbH, ModernaTX, Inc., SWOG Cancer Research Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline: 6 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Contrave	Contrave	marketed			Other
Xeloda	Xeloda	marketed		Thymidylate synthase	Oncology
Taxotere	Taxotere	marketed		Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor	Oncology
Rabbit antithymocyte globulin	Rabbit antithymocyte globulin	marketed
aMIL	aMIL	marketed	Personalized neoantigen vaccine	Patient-specific tumor neoantigens	Oncology
Lupron	Lupron	marketed			Other
Cisplatin + Gemcitabine	Cisplatin + Gemcitabine	phase 3	Chemotherapy combination (platinum agent + nucleoside analog)		Oncology
Azacitadine	Azacitadine	phase 3			Other

Therapeutic area mix

Oncology · 4
Other · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 shared drug class
Immatics Biotechnologies GmbH · 1 shared drug class
ModernaTX, Inc. · 1 shared drug class
SWOG Cancer Research Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:

Cite this brief

Drug Landscape (2026). Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins. Accessed 2026-05-17.